BrainsWay Ltd. (NASDAQ & TASE: BWAY) will report its second quarter 2026 financial results and operational highlights before the open of U.S. financial markets on Wednesday, August 12, 2026. The global leader in advanced noninvasive brain stimulation technologies aims to provide investors with an update on business operations alongside the financial data. This announcement sets the stage for market reaction to the company’s performance in the neurostimulation sector.

The company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results. Management will address questions regarding the Deep Transcranial Magnetic Stimulation (Deep TMS) platform and broader business strategy. The proceedings are designed to offer transparency into BrainsWay’s operational trajectory for the period.

Conference Call Details

Investors can access the conference call through dial-in or webcast options. The English-language broadcast will be available for replay for 30 days on the company’s website. Participants are advised to access the website at least 10 minutes ahead of time to register.

A separate Hebrew-language conference call is scheduled for Thursday, August 13, 2026, at 11:00 AM Israeli Daylight Time. This session will provide similar updates for stakeholders preferring Hebrew communication. The webcast link for this session is provided separately in the official release.

Business Overview

BrainsWay operates as a global leader in advanced noninvasive neurostimulation treatments for mental health disorders. The company utilizes its proprietary Deep TMS platform technology, which has obtained three FDA-cleared indications backed by pivotal clinical studies. Current indications include major depressive disorder (including anxious depression), obsessive-compulsive disorder, and smoking addiction. Additional clinical trials are underway for various psychiatric, neurological, and addiction disorders.

Founded in 2003, BrainsWay maintains operations in the United States and Israel. The company is committed to increasing global awareness of and broad access to Deep TMS treatments. Investors awaiting the Q2 2026 results will look for signs of continued adoption of these FDA-cleared indications across key markets.

BrainsWay Ltd. has made a $3 million minority equity investment in Radial Health, Inc., a management services organization supporting a network of Brain Medicine clinics. The investment was part of Radial's previously announced Series A financing round. BrainsWay joins other investors, including General Catalyst, Floating Point Capital, and Solari Capital, in supporting Radial's growth.

Radial specializes in developing clinical infrastructure, reimbursement tools, and an AI-guided decision support platform for noninvasive therapies like Deep TMS™. The financing is expected to support Radial's exploration of various M&A opportunities. BrainsWay's investment aligns with its strategy to secure minority stakes in high-performing mental health provider networks.

Hadar Levy, Chief Executive Officer of BrainsWay, stated that the investment represents continued execution of the company's strategic initiative to expand awareness of noninvasive mental health treatment. John Capecelatro, CEO and co-founder of Radial, expressed gratitude for the support, noting that the capital will help expand Radial's clinical footprint and technology platform.

Advocates Ami Hordes and Sarit Molcho of S. Friedman, Abramson & Co. Law Offices served as lead counsel for BrainsWay on the transaction. BrainsWay is a global leader in advanced noninvasive neurostimulation treatments, with FDA-cleared indications for major depressive disorder, obsessive-compulsive disorder, and smoking addiction.

The investment underscores BrainsWay's commitment to increasing global access to Deep TMS technology. Radial's platform aims to enhance the delivery of evidence-based Brain Medicine treatments for patients nationwide.